Dyne Therapeutics, Inc. (DYN) |
|
11.52 -0.06 (-0.52%)
|
03-31 16:00 |
|
Open: |
11.69 |
Pre. Close: |
11.58 |
|
High:
|
11.75 |
Low:
|
11.21 |
|
Volume:
|
392,224 |
Market Cap:
|
649(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:18:12 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 16.04 One year: 18.22 |
| Support: |
Support1: 10.72 Support2: 8.92 |
| Resistance: |
Resistance1: 13.73 Resistance2: 15.6 |
| Pivot: |
11.89  |
| Moving Average: |
MA(5): 11.25  MA(20): 12.46
MA(100): 12.34 MA(250): 10.69 |
| MACD: |
MACD(12,26): -0.6 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 22.6 %D(3): 15.7 |
| RSI: |
RSI(14): 40.3 |
| 52-week: |
High: 15.63 Low: 4.3 |
| Average Vol(K): |
3-Month: 320 (K) 10-Days: 509 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DYN ] has closed above bottom band by 38.4%. Bollinger Bands are 1.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.65 - 11.69 |
11.69 - 11.74 |
|
Low:
|
10.89 - 10.94 |
10.94 - 10.98 |
|
Close:
|
11.5 - 11.58 |
11.58 - 11.67 |
|
Company Description |
|
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.. |
Headline News |
Mon, 20 Mar 2023
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference - Yahoo Finance
Fri, 17 Mar 2023
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average ... - MarketBeat
Wed, 15 Mar 2023
Alpha Paradigm Partners LLC Invests $440000 in Dyne ... - MarketBeat
Thu, 09 Mar 2023
Avidity Biosciences: Helping Deliver Oligonucleotides Outside Liver ... - Seeking Alpha
Tue, 07 Mar 2023
Dyne Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Mon, 06 Mar 2023
The sale of 612,679 shares of Dyne Therapeutics, Inc. by Logos ... - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
56 (M) |
| Shares Float |
32 (M) |
|
% Held by Insiders
|
1.5 (%) |
|
% Held by Institutions
|
89.2 (%) |
|
Shares Short
|
3,770 (K) |
|
Shares Short P.Month
|
3,550 (K) |
Stock Financials |
|
EPS
|
-3 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.53 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-29.2 |
|
Return on Equity (ttm)
|
-54.2 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.01 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-154 (M) |
|
Levered Free Cash Flow
|
-98 (M) |
Stock Valuations |
|
PE Ratio
|
-3.85 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.53 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-4.23 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
